Comparison of the Everolimus Eluting (XIENCE-V, XIENCE-Prime or PROMUS Stent) With the Biolimus A9 Eluting NOBORI Stent in All-comers: a Randomized Open Label Study The COMPARE II Trial Imaging and Vasomotion Substudy.

Trial Profile

Comparison of the Everolimus Eluting (XIENCE-V, XIENCE-Prime or PROMUS Stent) With the Biolimus A9 Eluting NOBORI Stent in All-comers: a Randomized Open Label Study The COMPARE II Trial Imaging and Vasomotion Substudy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Everolimus (Primary) ; Umirolimus (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COMPARE-II
  • Most Recent Events

    • 01 Nov 2016 Results of five years follow-up of patients with ST-segment elevation (n=568) published in the Journal of the American College of Cardiology
    • 30 Jan 2013 Results published in the Lancet.
    • 15 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top